WSE:PCR

Stock Analysis Report

Executive Summary

PCC Rokita SA manufactures and distributes chemical products in Poland.

Snowflake

Fair value second-rate dividend payer.


Similar Companies

Share Price & News

How has PCC Rokita's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PCR's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-2.8%

PCR

-2.0%

PL Chemicals

-1.8%

PL Market


1 Year Return

-41.7%

PCR

-8.0%

PL Chemicals

-3.3%

PL Market

Return vs Industry: PCR underperformed the Polish Chemicals industry which returned -8% over the past year.

Return vs Market: PCR underperformed the Polish Market which returned -3.3% over the past year.


Shareholder returns

PCRIndustryMarket
7 Day-2.8%-2.0%-1.8%
30 Day-3.6%-3.4%-1.0%
90 Day-8.0%-8.0%1.9%
1 Year-35.9%-41.7%-5.0%-8.0%-0.2%-3.3%
3 Year-5.6%-26.7%-34.2%-40.5%12.4%4.1%
5 Year113.6%42.6%-25.4%-34.7%0.9%-11.5%

Price Volatility Vs. Market

How volatile is PCC Rokita's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is PCC Rokita undervalued compared to its fair value and its price relative to the market?

4.4%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PCR (PLN48.6) is trading below our estimate of fair value (PLN50.83)

Significantly Below Fair Value: PCR is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: PCR is good value based on its PE Ratio (6x) compared to the Chemicals industry average (11.3x).

PE vs Market: PCR is good value based on its PE Ratio (6x) compared to the Polish market (10.5x).


Price to Earnings Growth Ratio

PEG Ratio: PCR is poor value based on its PEG Ratio (3.1x)


Price to Book Ratio

PB vs Industry: PCR is overvalued based on its PB Ratio (1.4x) compared to the PL Chemicals industry average (0.7x).


Next Steps

Future Growth

How is PCC Rokita forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

1.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PCR's forecast earnings growth (1.9% per year) is below the savings rate (2.9%).

Earnings vs Market: PCR's earnings (1.9% per year) are forecast to grow slower than the Polish market (11% per year).

High Growth Earnings: PCR's earnings are forecast to grow, but not significantly.

Revenue vs Market: PCR's revenue (3.2% per year) is forecast to grow slower than the Polish market (5.7% per year).

High Growth Revenue: PCR's revenue (3.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PCR's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has PCC Rokita performed over the past 5 years?

26.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PCR has high quality earnings.

Growing Profit Margin: PCR's current net profit margins (10.7%) are lower than last year (15.6%).


Past Earnings Growth Analysis

Earnings Trend: PCR's earnings have grown significantly by 26.2% per year over the past 5 years.

Accelerating Growth: PCR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: PCR had negative earnings growth (-25.5%) over the past year, making it difficult to compare to the Chemicals industry average (33.1%).


Return on Equity

High ROE: Whilst PCR's Return on Equity (23.42%) is high, this metric is skewed due to their high level of debt.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is PCC Rokita's financial position?


Financial Position Analysis

Short Term Liabilities: PCR's short term assets (PLN424.5M) do not cover its short term liabilities (PLN466.8M)

Long Term Liabilities: PCR's short term assets (PLN424.5M) do not cover its long term liabilities (776.5M)


Debt to Equity History and Analysis

Debt Level: PCR's debt to equity ratio (121.8%) is considered high.

Reducing Debt: PCR's debt to equity ratio has increased from 51.1% to 121.8% over the past 5 years.

Debt Coverage: PCR's debt is well covered by operating cash flow (35.4%).

Interest Coverage: PCR's interest payments on its debt are well covered by EBIT (10.3x coverage).


Balance Sheet

Inventory Level: PCR has a high level of physical assets or inventory.

Debt Coverage by Assets: PCR's debt is not covered by short term assets (assets are 0.5x debt).


Next Steps

Dividend

What is PCC Rokita's current dividend yield, its reliability and sustainability?

17.10%

Current Dividend Yield


Dividend Yield vs Market

company17.1%marketbottom25%2.7%markettop25%7.4%industryaverage5.8%forecastin3Years8.4%

Current dividend yield vs market & industry

Notable Dividend: PCR's dividend (17.1%) is higher than the bottom 25% of dividend payers in the Polish market (2.68%).

High Dividend: PCR's dividend (17.1%) is in the top 25% of dividend payers in the Polish market (7.36%)


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, PCR has been paying a dividend for less than 10 years.

Growing Dividend: PCR's dividend payments have increased, but the company has only paid a dividend for 5 years.


Current Payout to Shareholders

Dividend Coverage: With its high payout ratio (102.8%), PCR's dividend payments are not well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: PCR's dividends in 3 years are forecast to be well covered by earnings (29.1% payout ratio).


Next Steps

Management

What is the CEO of PCC Rokita's salary, the management and board of directors tenure and is there insider trading?

zł1m

CEO Compensation


CEO

Wieslaw Klimkowski 0

0yrs

Tenure

zł1,346,498

Compensation

Mr. Wieslaw Klimkowski serves as the President of the Management Boards at Rokita S.A. and Silesia-Kalk Sp. z o.o. Mr. Klimkowski serves as President of the Management Board and Director of Investor Superv ...


CEO Compensation Analysis

Compensation vs Market: Wieslaw's total compensation ($USD0.00) is about average for companies of similar size in the Polish market ($USD0.00).

Compensation vs Earnings: Wieslaw's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Management Team

  • Wieslaw Klimkowski

    President of the Mgmt Board

    • Tenure: 0yrs
    • Compensation: zł1.35m
  • Marcin Suchanek

    Acting MD of the Energy Business Unit & Purchasing Director

    • Tenure: 0yrs
  • Rafal Zdon

    VP of the Management Board & Financial Director

    • Tenure: 9.8yrs
    • Compensation: zł1.24m
  • Robert Pabich

    Secretary of the Supervisory Board & Member of Supervisory Board

    • Tenure: 3.7yrs
    • Compensation: zł48.00k

Board Members

  • Alfred Pelzer (59yo)

    Chairman of the Supervisory Board

    • Tenure: 0yrs
  • Waldemar Preussner (59yo)

    Deputy Chairman of Supervisory Board

    • Tenure: 0yrs
  • Mariusz Dopierala

    Member of Supervisory Board

    • Tenure: 0yrs
    • Compensation: zł46.00k
  • Robert Pabich

    Secretary of the Supervisory Board & Member of Supervisory Board

    • Tenure: 3.7yrs
    • Compensation: zł48.00k
  • Arkadiusz Szymanek

    Member of Supervisory Board

    • Tenure: 1.9yrs

Company Information

PCC Rokita SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PCC Rokita SA
  • Ticker: PCR
  • Exchange: WSE
  • Founded:
  • Industry: Specialty Chemicals
  • Sector: Materials
  • Market Cap: zł984.724m
  • Shares outstanding: 19.85m
  • Website: https://www.pcc.rokita.pl

Location

  • PCC Rokita SA
  • ul. Sienkiewicza 4
  • Brzeg Dolny
  • 56-120
  • Poland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PCRWSE (Warsaw Stock Exchange)YesBearer SharesPLPLNJun 2014
0QVXLSE (London Stock Exchange)YesBearer SharesGBPLNJun 2014

Biography

PCC Rokita SA manufactures and distributes chemical products in Poland. The company offers chloralkali, raw materials, and intermediates; polyurethanes, including flame retardants, polyurethane systems, an ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/22 21:49
End of Day Share Price2019/11/22 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.